EDU 37 - ASTRO GI Guideline Session: Radiation Therapy for Gastric Cancer and Pancreatic Cancer: A Case-Based Interactive Discussion
MODERATOR(S)
Christopher Willett, MD, FASTRO - Duke University Medical Center
Daniel Chang, MD, FASTRO - University of Michigan
session DESCRIPTION
This is a case-based session designed to provide attendees with practical guidance on two new ASTRO gastrointestinal (GI) guidelines. The session will highlight key recommendations and guidance based on new evidence from the gastric cancer and pancreatic cancer guidelines. Gastric - Gastric cancer is the fifth most common malignancy globally and fifth in mortality with significant geographic variability. The treatment of gastric cancer is complex and multidisciplinary, employing surgery, systemic therapy and RT. Although other investigators and clinical societies have published guidelines for gastric cancer, there is a need for expert-based guidance on interpreting contemporary literature. This session will provide an in-depth overview clarifying the role of RT in the management of all stages of gastric cancer. Pancreas - Pancreatic cancer is projected to be the second leading cause of cancer-related mortality by 2030. Since publication of ASTRO's 2019 guideline, multiple randomized controlled trials have been published that have significantly influenced the standard of care for RT in the management of pancreatic cancer. In addition, RT techniques have evolved significantly since the publication of the prior ASTRO guidelines related to both dose and target volume escalation, facilitated by online adaptive RT and improved image guidance especially with MRI. These technical advances have led to promising outcomes and potentially new indications for RT in pancreatic cancer management. We plan to present updated pancreatic cancer guidelines that reflect these important changes since the publication of the prior ASTRO guidelines.
learning objectives
- Identify appropriate clinical indications for RT in pancreatic and gastric cancer management.
- Determine optimal RT dose and technique for pancreatic and gastric cancer.
- Implement optimal systemic therapy regimens with or without RT for resectable, non-metastatic locoregionally advanced gastric cancer patients.
Credits
| AMA PRA Category 1 Credits: | 1.25 |
Presentations
-
12:30pm - 12:32pm ETSpeaker: Christopher Willett, MD, FASTRO - Duke University Medical Center, Durham
-
12:32pm - 01:02pm ETSpeaker: Christopher Anker, MD - University of Vermont Medical Center, Burlington
-
01:02pm - 01:32pm ETSpeaker: Michael Chuong, MD - Miami Cancer Institute at Baptist Health South Florida, Miami
-
01:32pm - 01:45pm ETSpeaker: Daniel Chang, MD, FASTRO - University of Michigan, Ann Arbor